Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase III Trial for Chronic Obstructive Pulmonary Disease (“COPD”)

SHANGHAI, April 6, 2023 /PRNewswire/ — Nuance Pharma (“the Company”) announces dosing of first patient in the ENHANCE – China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) of its novel solution Ensifentrine in mainland China. Ensifentrine…